This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Andres J. Pumariega, MD; Betty Muller, MD; Noel Rivers-Bulkeley, MD

JAMA. 1982;248(23):3141-3142.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

AMOXAPINE is a new antidepressant approved for marketing in the United States just over a year ago. It is structurally similar to both loxapine succinate and imipramine hydrochloride, and its mechanism of action is through blocking the reuptake of norepinephrine primarily and serotonin secondarily as well as having a dopamine-receptor blocking effect. It has become one of the most popular antidepressants in use today, largely because of its low incidence of side effects and toxic reactions and its possible earlier onset of action.^1-5 Our recent experience with a patient who ingested excessive amounts of this drug has alerted us to a yet unreported and potentially lethal complication of amoxapine overdose.

Report of a Case

A 17-year-old girl was transferred to Vanderbilt University Medical Center, Nashville, Tenn, from an outlying hospital after ingesting at least 4 g of amoxapine (approximately 60 mg/kg) in an impulsive suicide gesture. She had been . . . [Full Text PDF of this Article]

Author Affiliations
From the Departments of Psychiatry (Drs Pumariega, Muller, and Rivers-Bulkeley) and Pediatrics (Dr Pumariega), Vanderbilt University Medical Center, Nashville, Tenn.

Footnotes
Reprint requests to Division of Child & Adolescent Psychiatry, Vanderbilt University Medical Center, 243 Medical Center South, Nashville, TN 37212 (Dr Pumariega).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?